Burcu Zeydan

Dr. Burcu Zeydan

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
TDTaskin Duman
Taskin Duman
DUDerya Uluduz
Derya Uluduz
IMIpek Midi
Ipek Midi
HBHesna Bektas
Hesna Bektas
YKYuksel Kablan
Yuksel Kablan
NUNevzat Uzuner
Nevzat Uzuner

2 March 2023 in Brain
Verified
Journal Article
Closed access
PDF file
CLChristine Lebrun-Frénay
Christine Lebrun-Frénay
DODarin T Okuda
Darin T Okuda
ASAksel Siva
Aksel Siva
CLCassandre Landes-Chateau
Cassandre Landes-Chateau
CAChristina J Azevedo
Christina J Azevedo
OKOrhun H Kantarci
Orhun H Kantarci
The radiologically isolated syndrome (RIS) was defined in 2009 as the presence of asymptomatic, incidentally identified demyelinating-appearing white matter lesions in the CNS within individuals lacking symptoms typical of multiple sclerosis (MS). The RIS criteria have been validated and predict the transition to symptomatic MS reliably. The performance of RIS criteria that require fewer MRI lesions is unknown. 2009-RIS subjects, by definition, fulfil three to four of four criteria for 2005 dissemination in space (DIS) and subjects fulfilling only one or two lesions in at least one 2017 DIS location were identified within 37 prospective databases. Univariate and multivariate Cox regression models were used to identify predictors of a first clinical event. Performances of different groups were calculated. Seven hundred and forty-seven subjects (72.2% female, mean age 37.7 ± 12.3 years at the index MRI) were included. The mean clinical follow-up time was 46.8 ± 45.4 months. All subjects had focal T2 hyperintensities suggestive of inflammatory demyelination on MRI; 251 (33.6%) fulfilled one or two 2017 DIS criteria (designated as Groups 1 and 2, respectively), and 496 (66.4%) fulfilled three or four 2005 DIS criteria representing 2009-RIS subjects. Group 1 and 2 subjects were younger than the 2009-RIS group and were more likely to develop new T2 lesions over time (P < 0.001). Groups 1 and 2 were similar regarding survival distribution and risk factors for transition to MS. At 5 years, the cumulative probability for a clinical event was 29.0% for Groups 1 and 2 compared to 38.7% for 2009-RIS (P = 0.0241). The presence of spinal cord lesions on the index scan and CSF-restricted oligoclonal bands in Groups 1–2 increased the risk of symptomatic MS evolution at 5 years to 38%, comparable to the risk of development in the 2009-RIS group. The presence of new T2 or gadolinium-enhancing lesions on follow-up scans independently increased the risk of presenting with a clinical event (P < 0.001). The 2009-RIS subjects or Groups 1 and 2 with at least two of the risk factors for a clinical event demonstrated better sensitivity (86.0%), negative predictive value (73.1%), accuracy (59.8%) and area under the curve (60.7%) compared to other criteria studied. This large prospective cohort brings Class I evidence that subjects with fewer lesions than required in the 2009 RIS criteria evolve directly to a first clinical event at a similar rate when additional risk factors are present. Our results provide a rationale for revisions to existing RIS diagnostic criteria.

1 January 2019 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
BZBurcu Zeydan
Burcu Zeydan
NTNirubol Tosakulwong
Nirubol Tosakulwong
CSChristopher G. Schwarz
Christopher G. Schwarz
MSMatthew L. Senjem
Matthew L. Senjem
JGJeffrey L. Gunter
Jeffrey L. Gunter
KKKejal Kantarci
Kejal Kantarci
Women who undergo bilateral salpingo-oophorectomy (BSO) before the onset of menopause have an accelerated accumulation of multimorbidity, with an increased risk of aging-associated neurological diseases, including dementia.1-3 Furthermore, surgical menopause at an early age was associated with Alzheimer disease (AD) pathology at autopsy.4 Because imaging biomarkers associated with cognitive impairment and dementia precede the clinical symptoms, and may provide insight into the underlying causative mechanisms of cognitive impairment and dementia later in life, we investigated β-amyloid deposition (primary outcome), magnetic resonance imaging (MRI)–based biomarkers of medial temporal lobe neurodegeneration, and white matter hyperintensity volume in women who underwent BSO before age 50 years and before reaching natural menopause.

26 May 2020 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
BZBurcu Zeydan
Burcu Zeydan
OKOrhun H. Kantarci
Orhun H. Kantarci

1 March 2018 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
BZBurcu Zeydan
Burcu Zeydan
XGXinyi Gu
Xinyi Gu
EAElizabeth J. Atkinson
Elizabeth J. Atkinson
BKB. Mark Keegan
B. Mark Keegan
BWBrian G. Weinshenker
Brian G. Weinshenker
OKOrhun H. Kantarci
Orhun H. Kantarci
Objective To assess whether cervical spinal cord atrophy heralds the onset of progressive MS. Methods We studied 34 individuals with radiologically isolated syndrome (RIS) and 31 patients with relapsing-remitting MS (RRMS) age matched to 25 patients within a year of onset of secondary progressive MS (SPMS). Two raters independently measured (twice per rater) the cervical spinal cord average segmental area (CASA) (mm2) of axial T2-weighted images between C2 and C7 landmarks. The midsagittal T2-weighted image from the end of C2 to the end of C7 vertebra was used to measure the cervical spine (c-spine) length (mm). Sex, age at cervical MRI, number and location of cervical spinal cord lesions, c-spine length, and diagnoses were analyzed against the outcome measures of CASA and C2 and C7 slice segmental areas. Results Intrarater and interrater agreement was excellent (intraclass correlation coefficient >0.97). The CASA area (p = 0.03) and C7 area (p = 0.002) were smaller in SPMS compared with RRMS. The C2 area (p = 0.027), CASA (p = 0.004), and C7 area (p = 0.003) were smaller in SPMS compared with RIS. The C2 area did not differ between SPMS and RRMS (p = 0.09). The C2 area (p = 0.349), CASA (p = 0.136), and C7 area (p = 0.228) did not differ between RIS and MS (SPMS and RRMS combined). In the multivariable model, ≥2 cervical spinal cord lesions were associated with the C2 area (p = 0.008), CASA (p = 0.009), and C7 area independent of disease course (p = 0.017). Progressive disease course was associated with the C7 area independent of the cervical spinal cord lesion number (p = 0.004). Conclusion Cervical spinal cord atrophy is evident at the onset of progressive MS and seems partially independent of the number of cervical spinal cord lesions. Classification of evidence This study provides Class III evidence that MRI cervical spinal cord atrophy distinguishes patients at the onset of progressive MS from those with RIS and RRMS.

1 October 2016 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
BZBurcu Zeydan
Burcu Zeydan
UUUgur Uygunoglu
Ugur Uygunoglu
SSSabahattin Saip
Sabahattin Saip
ODOnat N. Demirci
Onat N. Demirci
ESEmire Seyahi
Emire Seyahi
OKOrhun H. Kantarci
Orhun H. Kantarci
Objective: We evaluated the effectiveness of infliximab in patients with neuro-Behçet syndrome for whom other immunosuppressive medications had failed. Methods: Patients whose common immunosuppressive medications fail in recurrent neuro-Behçet syndrome need an alternative. We report our experience with the tumor necrosis factor α blocker infliximab for long-term treatment of neuro-Behçet syndrome. We recruited patients within a multidisciplinary referral practice of Behçet disease and prospectively followed everyone with a neurologic symptom(s). Patients (n = 16) with ≥2 neurologic bouts (excluding purely progressive disease) while on another immunosuppressive treatment were switched to and successfully sustained on infliximab (5 mg/kg in weeks 0, 2, and 6, then once every 8 weeks; minimum follow-up duration ≥12 months). Infliximab was stopped within 2 months after initiation in one patient because of pulmonary and CNS tuberculosis. Results: Patients had stepwise worsening due to relapses in the Expanded Disability Status Scale modified for neuro-Behçet syndrome before switching to infliximab (median score of 5.0, range 2.0–7.0; median neuro-Behçet syndrome duration 29.1 months, range 5.0–180.7). Median duration of preinfliximab immunosuppressive medication use was 20.0 months (range 3.0–180.7). In all 15 patients, during infliximab treatment (median score 4.0, range 2.0–7.0; median duration 39.0 months, range 16.0–104.9 months), neurologic relapses were completely aborted and there was no further disability accumulation. Conclusion: We observed a significant beneficial effect of infliximab in neuro-Behçet syndrome. Classification of evidence: This study provides Class IV evidence that for patients with neuro-Behçet syndrome whose other immunosuppressive medications failed, infliximab prevents further relapses and stabilizes disability.